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Abstract
Background: Multipotent stem cells exist within adipose tissue throughout life. An abnormal
recruitment of these adipose precursor cells could participate to hyperplasia of adipose tissue
observed in severe obesity or to hypoplasia of adipose tissue observed in lipodystrophy. Therefore,
pharmacological molecules that control the pool of stem cells in adipose tissue are of great interest.
Glycogen Synthase Kinase (GSK) 3 has been previously described as involved in differentiation of
preadipose cells and might be a potential therapeutic target to modulate proliferation and
differentiation of adipocyte precursors. However, the impact of GSK3 inhibition on human adipose-
derived stem cells remained to be investigated. The aim of this study was to investigate GSK3 as a
possible target for pharmacological inhibition of stem cell adipogenesis. To reach this goal, we
studied the effects of pharmacological inhibitors of GSK3, i.e. lithium chloride (LiCl) and BIO on
proliferation and adipocyte differentiation of multipotent stem cells derived from human adipose
tissue.
Results: Our results showed that GSK3 inhibitors inhibited proliferation and clonogenicity of
human stem cells, strongly suggesting that GSK3 inhibitors could be potent regulators of the pool
of adipocyte precursors in adipose tissue. The impact of GSK3 inhibition on differentiation of
hMADS cells was also investigated. Adipogenic and osteogenic differentiations were inhibited upon
hMADS treatment with BIO. Whereas a chronic treatment was required to inhibit osteogenesis, a
treatment that was strictly restricted to the early step of differentiation was sufficient to inhibit
adipogenesis.
Conclusion: These results demonstrated the feasibility of a pharmacological approach to regulate
adipose-derived stem cell function and that GSK3 could represent a potential target for controlling
adipocyte precursor pool under conditions where fat tissue formation is impaired.
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Background
Obesity, which is characterized by an excess of adipose
mass, is a major public health-problem. Hypertrophy, i.e.
increase in the adipocyte size and hyperplasia, i.e. increase
in the adipocyte numbers, are observed in severe obesity.
It is now well established that multipotent stem cells exist
within adipose tissue throughout the life [1-3] and that an
excessive recruitment of these adipose precursor cells
could lead to hyperplasia. As opposed to hypertrophy,
hypoplasia of adipose tissue is observed in lipodystrophy
and is associated with diabetes and hyperlipidaemia. Adi-
pocytes and osteoblasts share the same mesenchymal pre-
cursor cell [4]. Adipogenesis and osteogenesis are
processes that respond to a balance in bone marrow and
this balance can be disrupted under pathological condi-
tions such as osteoporosis where adipocytes develop at
the expense of osteoblasts [5]. Therefore, pharmacological
molecules that control the pool of adipose stem cells are
of great interest.
Glycogen synthase kinase 3 (GSK3), a serine/threonine
kinase existing in two isoforms GSK3α and GSK3β, is a
key regulator of numerous signalling pathways. In partic-
ular, GSK3 has been involved in multiple cellular proc-
esses including Wnt and Hedgehog (Hh) pathways. In the
activation of the canonical Wnt pathway, inhibition of
GSK3 results in dephosphorylation of β-catenin leading to
its nuclear accumulation. Inhibition of GSK3 also contrib-
utes to activation of the Hh pathway by stabilisation of Gli
2/3 transcription factors, favouring their nuclear translo-
cation and leading to transcription of target genes. Gli1 is
one of them and induction of Gli1 gene expression has
been characterized as a reliable marker of Hh signalling
activity [6]. The role of GSK3 in the differentiation of
preadipose cells has been previously described. It has
been shown that activation of the Wnt pathway via inhi-
bition of GSK3 inhibits adipogenesis of murine preadi-
pocytes and in mice [7,8]. Expression of Hh target genes
was reduced in fat depots of obese mice, suggesting anti-
adipogenic properties of this pathway [9]. GSK3 is also a
key component of the circadian apparatus. The circadian
clock may play a role in adipocyte metabolism and it has
been recently shown that inhibition of GSK3 in human
adipocytes lengthened the period of expression of core cir-
cadian transcriptional apparatus [10]. Therefore, GSK3
could represent a potential therapeutic target to modulate
proliferation and differentiation of adipocyte precursors.
However, the impact of GSK3 inhibition on human adi-
pose-derived stem cells remained to be investigated. To
address this point we have studied the effects of two phar-
macological inhibitors of GSK3, lithium chloride (LiCl)
[11] and 6-bromoindirubin-3'-oxime (BIO) [12], on
multipotent stem cells derived form human adipose tissue
(hMADS cells, also named ASC as suggested by IFATS, a
society focusing on Adipose-derived Stem or Stromal
Cells, and discussed by Mitchell et al. [13]. We have previ-
ously established the procedure to isolate and expand
hMADS cells from different donors. hMADS cells exhibit
key features of mesenchymal stem cells such as self-
renewal capacity and ability to undergo differentiation at
the single cell level into at least two lineages (adipogenic
and osteogenic) [14,15]. Thus, hMADS cells represent a
potent cellular model to investigate pathways regulating
self-renewal, adipogenesis and osteogenesis [16,17].
Results and Discussion
Functional inhibition of GSK3 in human adipose-derived 
stem cells
In order to determine the effective concentrations of BIO
and LiCl, nuclear translocation of β-catenin and induction
of Gli1 gene expression have been analyzed in hMADS2
and hMADS3 cells, two stem cell populations isolated
from separate donors. As shown in Fig 1A, stimulation of
GSK3 inhibitors induced β-catenin nuclear translocation and  Gli1 gene expression Figure 1
GSK3 inhibitors induced β-catenin nuclear transloca-
tion and Gli1 gene expression. hMADS3 cells were main-
tained in proliferation medium supplemented with 0.5% FCS, 
then localisation of β-catenin was revealed after treatment 
with 0.5 μM BIO or 0.5 μM MeBIO for 24 hours. DAPI was 
used to label nuclei (A). hMADS2 and hMADS3 cells were 
maintained as in (A) and fold induction in the expression of 
Gli1 gene was quantified by real-time PCR 24 hours after 
treatment with 0.5 μM BIO, 0.5 μM MeBio, 20 mM LiCl or 
20 mM NaCl or under control condition (Ctr). Bars are the 
means ± S.E of 2 independent experiments, **: p < 0.01 (B).BMC Cell Biology 2008, 9:11 http://www.biomedcentral.com/1471-2121/9/11
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hMADS3 cells with 0.5 μM BIO led to nuclear accumula-
tion of β-catenin, whereas the inactive BIO molecule
(MeBio [12]) had no effect. Under our culture conditions,
0.1 μM BIO had no effect on β-catenin stabilization and 5
μM led to cell death (not shown). Treatment of cells with
20 mM LiCl had the same effect than 0.5 μM BIO whereas
10 mM LiCl and 20 mM sodium chloride (NaCl) had no
effect (not shown). Nucleofection of hMADS3 cells with a
reporter gene under the control of Tcf/Lef response-ele-
ment showed that the β-catenin pathway was activated in
hMADS cells after inhibiting GSK3 (see Additional file 1).
Gli1 gene expression was also stimulated in hMADS3 and
hMADS2 cells that were maintained in the presence of 0.5
μM BIO or 20 mM LiCl (Fig. 1B).
Effect of GSK3 inhibitors on proliferation of human 
adipose-derived stem cells
Then, the functional consequence of GSK3 inhibition on
proliferation of hMADS cells has been investigated. Mor-
phology of hMADS cells changed after treatment with 0.5
μM BIO or 20 mM LiCl. From a fibroblastic-like morphol-
ogy, GSK3 inhibitor-treated cells displayed a cuboidal
shape (see Additional file 2). We did not observe any
change in morphology or any effect on proliferation when
cells were treated with 0.1 μM BIO (not shown). In con-
trast, at a higher concentration of 0.5 μM BIO, treatment
of hMADS2 cells for 5 days led to a 40–50% inhibition of
proliferation. Effects of BIO on cell morphology and pro-
liferation were reversible indicating that the GSK3 inhibi-
tor did not affect cell viability (not shown). MeBio-treated
cells did not display any significant inhibition of prolifer-
ation. The inhibitory effect of BIO was also observed after
treatment of mesenchymal stem cells isolated from
human bone-marrow (hMSCs) (Fig. 2A). BIO-inhibitory
effect was detected as early as 3 days after treatment and
was reproducible on hMADS3 cells (Fig. 2B). Inhibition
on hMADS3 cell proliferation was also observed to a sim-
ilar extent after treatment with 20 mM LiCl but not with
NaCl (Fig. 2C). As shown in Fig. 3, BIO inhibited the abil-
ity of hMADS cells and hMSCs to proliferate at the single
Impact of GSK3 inhibition on the proliferation of hMADS cells Figure 2
Impact of GSK3 inhibition on the proliferation of hMADS cells. Cell number after treatment of hMADS3 cells for 5 
days (A) or 3 days (B, C) with indicated compounds. hMADS cells were maintained in 0.5% FCS whereas hMSCs were main-
tained in medium supplemented with 10% FCS. Bars are the means ± SE of 3 independent experiments. *: p < 0.05, **: p <0.01, 
***: p < 0.001BMC Cell Biology 2008, 9:11 http://www.biomedcentral.com/1471-2121/9/11
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cell level, a crucial feature of stem cells. This indicates that
BIO cannot be used to expand mesenchymal stem cells ex
vivo. This is in contrast with a previous report showing that
BIO was able to maintain pluripotent embryonic stem
cells by activating Wnt pathway [18] and that inhibition
of  β-catenin promotes proliferation of uncharacterized
stromal cells of adipose tissue [19]. These discrepancies
could be due to a differential effect of Wnt pathway in
embryonic versus human adult mesenchymal stem cells
or/and to the fact that, as shown above, BIO activated
both Wnt and Hh pathways within the same cell popula-
tion. The effect of Hh pathway on proliferation on
hMADS cells remains to be investigated. In addition, as
also shown above, GSK3 is involved in several pathways
and we cannot rule out that BIO could have other targets
than GSK3 in hMADS cells. Altogether, these data show
that BIO inhibited the proliferation of human stem cells,
strongly suggesting that GSK3 inhibitors could be potent
regulators of the pool of adipocyte precursors in adipose
tissue.
Effects of BIO on differentiation of human adipose-derived 
stem cells
To investigate the effect of GSK3 inhibition on adipocyte
differentiation, hMADS cells were induced to differentiate
in the presence of BIO or MeBIO. Adipocytes and osteob-
lasts share the same mesenchymal precursor cell. Adipo-
genesis and osteogenesis are processes that respond to a
balance in bone marrow and this balance can be disrupted
under pathological conditions such as osteoporosis in
which adipocytes develop at the expense of osteoblasts
[5,20]. We took advantage of hMADS cells that were pre-
viously demonstrated to differentiate in vitro into func-
tional adipocytes and osteoblasts [16,17], to investigate
the effect of GSK3 inhibition on both lineages.
Adipogenic and osteogenic differentiations, as indicated
by Oil Red O and Alizarin staining respectively, were dra-
matically inhibited in the presence of BIO, whereas
MeBIO did not display any significant effect (Fig. 4, left
panel). BIO-inhibitory effect was quantified using enzy-
matic activities such as glycerol-3-dehydrogenase
(GPDH), which is expressed in adipocytes but not in oste-
oblasts, and alkaline phosphatase (ALP) activity, which is
expressed in osteoblasts but not in adipocytes. As shown
in Fig. 4, GPDH activity was inhibited when hMADS cells
were maintained for 10 days in adipogenic medium or in
a medium allowing simultaneously adipogenic and oste-
ogenic differentiations supplemented with BIO. ALP
activity was also inhibited when cells were maintained in
osteogenic or adipogenic/osteogenic media supple-
mented with the GSK3 inhibitor (Fig. 4, right panel).
Then, we investigated the impact of BIO treatment during
cell proliferation on subsequent differentiation. Quantifi-
cation of GPDH enzymatic activity indicated that cells
previously treated with BIO during proliferation dis-
played a lower capacity to undergo adipocyte differentia-
tion than untreated- or MeBio-treated cells (see
Additional file 3). This result indicates that GSK3 plays a
role in maintaining the differentiation potential of undif-
ferentiated hMADS cells. This is reminiscent of our previ-
ous work showing the critical role of FGF2 pathway on
self-renewal of hMADS cells [14].
Finally, analysis of adipocyte- and osteoblast-gene expres-
sion confirmed that treatment of hMADS cells with of BIO
during differentiation led to the inhibition of both differ-
entiation programs. As shown in Fig. 5, all of the genes
known to be expressed during adipocyte differentiation
that we have analyzed were inhibited in the presence of
BIO. Genes expressed during osteogenesis were also
inhibited by BIO, although at a lower extent compared to
adipogenesis-related genes. Altogether, these results are in
agreement with previous reports showing that activation
of Wnt or Hh pathways precludes differentiation of
murine 3T3-L1 preadipose cells into adipocytes [9,21].
Effects of BIO on hMADS3 cell clonogenicity Figure 3
Effects of BIO on hMADS3 cell clonogenicity. hMADS 
cells and hMSCs were plated at clonal density and maintained 
in medium supplemented with 10% FCS (Ctr). One day after 
cell plating, 0.5 μM BIO was added to the culture medium. 
Fifteen days later, the number of colonies was scored. Bars 
represent means of 2 independent experiments. **: p < 0.01, 
***: p < 0.001BMC Cell Biology 2008, 9:11 http://www.biomedcentral.com/1471-2121/9/11
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Our data indicate that the GSK3 inhibitor was a potent
inhibitor of commitment of human preadipocyte precur-
sors into the adipogenic lineage. The effect of Wnt path-
way on osteogenesis remains more controversial. Wnt has
been reported to enhance osteogenic differentiation of
murine mesenchymal stem cells [22]. More recently, Cho
et al. have shown that Wnt signalling suppresses osteo-
genic differentiation of stroma cells isolated from human
adipose tissue [19]. Therefore, the effect of Wnt signalling
on bone formation seems different in human versus
mouse and our data with BIO-treated hMADS cells are in
agreement with a negative effect of Wnt on osteogenesis of
human cells.
It has been observed that patients treated with LiCl for
bipolar disorder display weight gain and reduced risk of
fractures, suggesting that LiCl promotes both adipogene-
sis and osteogenesis in humans in vivo [23,24]. However,
a central effect of LiCl and an indirect effect on adipocytes
and osteoblasts in these patients cannot be excluded.
Differential effects of BIO treatment during early steps of 
adipogenesis and osteogenesis
Then, we analyzed BIO-inhibition on adipogenic and
osteogenic differentiations of hMADS cells more precisely
in order to address whether a chronic treatment with the
inhibitor was required. For that purpose, we treated
hMADS cells during the first 3 days of differentiation and
analyzed the impact of this treatment on GPDH and ALP
enzymatic activities as well as on the expression of specific
markers. In regards to adipogenesis, treatment of hMADS
cells for the first 3 days only was sufficient to inhibit
GPDH activity measured at day 10 (Fig. 6A). Analysis of
adipocyte gene expression confirmed that the inhibitory
effect of BIO after 3 days of treatment persisted at day 10
for most of the genes analyzed (Fig. 6B). In contrast, a
treatment restricted to the first 3 days had no effect on
both osteogenic markers such as ALP enzymatic activity
and expression of several genes known to play a role in
osteogenesis. Altogether, data indicate that treatment of
hMADS cells with BIO during the early step of differenti-
ation only led to inhibition of late steps of adipogenesis,
whereas it had no effect on osteogenesis. This strongly
suggests that the molecular mechanisms underlying inhi-
Effects of BIO on the adipogenic and osteogenic potential of hMADS cells Figure 4
Effects of BIO on the adipogenic and osteogenic potential of hMADS cells. hMADS3 cells were induced to undergo 
differentiation into adipocytes (Ad.) or osteoblasts (Os) or both (Ad./Os.) in the absence (Ctr) or presence of 0.5 μM BIO or 
0.5 μM MeBIO. Ten days later, cells were stained with Oil Red O for adipocytes or with Alizarin red for osteoblasts (left 
panel). Effects of the compounds on GPDH, expressed in adipocytes only, and ALP, expressed in osteoblasts only, enzymatic 
activities are shown (right panel). Bars are the means ± SE of 3 independent experiments. *: p < 0.05, **: p < 0.01BMC Cell Biology 2008, 9:11 http://www.biomedcentral.com/1471-2121/9/11
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bition of adipogenic and osteogenic differentiation by
BIO are different.
Identification of mechanisms leading to the differential
effects on adipogenesis and osteogenesis of hMADS cells
could lead to a preferential use of the GSK3 inhibitors on
adipocyte differentiation in vivo. In conclusion, our data
strongly suggest that GSK3 is a promising pharmacologi-
cal target to regulate both the number and differentiation
of adipocyte precursors in human adipose tissue. How-
ever, we have to keep in mind that potential adverse
effects could be observed due to the fact that GSK3 is
implicated in numerous signalling pathways. Therefore, it
would be important in the future to identify the signalling
pathway mediating the adipogenic effect of GSK3.
Conclusion
We have shown that BIO and LiCl, two inhibitors of
GSK3, inhibited proliferation as well as adipogenic and
osteogenic differentiations of stem cells isolated from
human adipose tissue. Data demonstrate the feasibility of
a pharmacological approach to regulate adipose-derived
stem cell function.
Methods
Isolation and culture of hMADS cells
hMADS cells were obtained from the stroma of human
adipose tissue as described previously [15]. Adipose tissue
was collected, with the informed consent of the parents, as
surgical scraps from surgical specimen of various surger-
ies, as approved by the Centre Hospitalier Universitaire de
Nice Review Board. The cell populations that have been
studied in this work were isolated from the pubic region
fat pad of a 5-year old (hMADS2) and of a 4-month old
(hMADS3) male donor. Proliferation medium for routine
maintenance of hMADS cells is composed of DMEM (low
glucose) containing 10% foetal calf serum, 10 mM
HEPES, 100 U/ml penicillin and streptomycin and sup-
plemented with FGF2 as previously reported [14]. After
reaching 80% confluence, adherent cells were dissociated
in 0.25% trypsin EDTA and seeded at 4500 cells/cm2.
Cells have been maintained in low serum concentration
for studying effects of GSK3 inhibitors on proliferation.
This medium is composed of 60% DMEM low glucose,
40% MCDB-201, insulin (10 μg/ml), transferrine(5 μg/
ml), selenium(50 ng/ml), dexamethasone (10-9M), ascor-
bic sodium acid (50 μg/ml), 2.5 ng/ml FGF2 and supple-
mented with 0.5% FCS. This medium containing a low
serum concentration allows the maintenance of stem cell
features of hMADS2 and hMADS3 cells (not shown).
Human mesenchymal stromal cells isolated from bone
marrow, termed hBMSC, were purchased from Cambrex
and used as recommended by the manufacturer. Cultures
were maintained at 37°C in a humidified gassed incuba-
tor, 5% CO2 in air.
hMADS cell differentiation
Adipocyte differentiation was performed as described pre-
viously [16]. Basically, confluent cells were cultured in
DMEM/Ham's F12 media supplemented with transferrin
(10  μg/ml), insulin (0.86 μM), triiodothyronine (0.2
nM), dexamethasone (1 μM), isobutyl-methylxanthine
(100 μM) and rosiglitazone (500 nM). Three days later,
the medium was changed (dexamethasone and isobutyl-
methylxanthine were omitted). Neutral lipid accumula-
tion was assessed by Oil red O staining [25]. For osteob-
lasts, confluent cells were cultured in α-MEM medium
containing 10% FCS, L-ascorbic acid phosphate (50 μg/
ml), β-glycerophosphate (10 mM) and 100 nM dexame-
thasone. Alizarin red staining was performed as previ-
ously described [25]. For simultaneous adipocyte and
osteoblast differentiations, confluent cells were cultured
in the differentiation medium consisting in 50% adipo-
genic and 50% osteogenic media.
Measurement of adipogenic and osteogenic specific 
enzymatic activities
Cell homogenates for both Glycerol-3-phosphate dehy-
drogenase (GPDH) and Alkaline phosphatase (ALP) enzy-
Effects of BIO on expression of adipogenic and osteogenic  genes Figure 5
Effects of BIO on expression of adipogenic and osteo-
genic genes. hMADS3 cells were induced to undergo differ-
entiation into adipocytes (left panel) or osteoblasts (right 
panel) in the presence of 0.5 μM BIO or 0.5 μM MeBIO. Ten 
days later, RNAs were prepared and expression of adipo-
genic or osteogenic markers was checked by qPCR. Results 
are the log2 inductions of BIO treated cells versus MeBIO 
treated cells. Expression data are colour-coded according to 
the scale.BMC Cell Biology 2008, 9:11 http://www.biomedcentral.com/1471-2121/9/11
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matic activity measurements were prepared in 20 mM
Tris-HCl pH 7.5 buffer containing 1 mM EDTA and 1 mM
2-mercaptoethanol. GPDH activity was measured by the
absorbance at 340 nm as described previously [26] and
ALP activity was assayed using the p-Nitrophenyl Phos-
phate Liquid Substrate System (Sigma). Absorbance was
measured at 412 nm.
Cell proliferation assays
Cells were plated onto 12-well plates (104 cells per well).
GSK3 inhibitors were added 24 hours after cell plating in
order to avoid a potential effect of the compounds on the
efficiency in cell attachment. After the appropriate time,
cells were trypsinized as mentioned above and counted
with a Coulter counter. For each experiment, three wells
per condition were counted.
Effects of BIO treatment during the first 3 days of differentiation on adipogenic and osteogenic abilities of hMADS cells Figure 6
Effects of BIO treatment during the first 3 days of differentiation on adipogenic and osteogenic abilities of 
hMADS cells. hMADS3 cells were induced to undergo differentiation into the indicated lineages in the presence of BIO and 
MeBIO during the first 3 days. Then, compounds were withdrawn and GPDH and ALP enzymatic activities were quantified at 
day 10. *: p < 0.05, **: p < 0.01, NS: not significant (A). hMADS3 cells were induced to undergo differentiation into adipocytes 
(upper panel) or osteoblasts (lower panel) as in A) and RNAs were prepared at day ten. The expression of molecular markers 
was checked by qPCR (B). Results are the log2 inductions of BIO treated cells versus MeBIO treated cells. Expression data are 
colour-coded according to the scale that is displayed.BMC Cell Biology 2008, 9:11 http://www.biomedcentral.com/1471-2121/9/11
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Clonal assays
Cells were plated at a density of 10 cells/cm2 in 100-mm2
dishes. 15 days after plating cells were fixed with 0.25%
glutaraldehyde and stained with 0.1% crystal violet. Col-
onies containing at least 40 cells were enumerated under
a light microscope. Medium was changed 3 times a week.
Immunocytochemistry
hMADS cells were rinsed twice with PBS at 4°C, and fixed
with 4% paraformaldehyde in PBS for 15 min at room
temperature. Free aldehydes were quenched by a 15-min
incubation with 1 M glycine in PBS. Fixed cells were per-
meabilized with 0.5% Triton for 10 min, and unspecific
reactions blocked with 5% bovine serum albumin in PBS
for 30 min. Cells were then incubated for 1 h with an anti
β-catenin (Santa Cruz Biotechnology) antibody diluted in
5% bovine serum albumin in PBS, followed by a 488-
Alexa Fluor conjugated secondary antibody. Nuclei were
counterstained with DAPI. Images were taken on an
LSM510 META confocal microscope (Zeiss).
RT-PCR analysis
Total RNA was extracted using TRI-Reagent™ kit (Eurome-
dex, France) according to the manufacturer's instructions
and RT-PCR analysis was conducted as described previ-
ously [14]. All primers sequences, designed using Primer
Express software (Applied Biosystems, France), see Addi-
tional file 4. For quantitative PCR, final reaction volume
was 25 μl, including specific primers (0.4 μM), 5 ng of
reverse transcribed RNA and 12.5 μl SYBR green master
mix (Applied Biosystems, France). Quantitative PCR con-
ditions were as follows: 2 min at 50°C, 10 min at 95°C,
followed by 40 cycles of 15 sec at 95°C, 1 min at 60°C.
Real-time PCR assays were run on an ABI Prism 7000 real-
time PCR machine (Applied Biosystems, France). Nor-
malization was performed using the geometrical average
of the housekeeping genes G6PDH, POLR2A and TBP.
Quantification was performed using the comparative-ΔCt
method. Level of expression was represented using the
genesis software [27]. This software generates expression
images using a colour code according to the expression
intensities.
Statistical analysis
Statistical significance was checked by using t-tests when-
ever comparing two conditions or a one-way ANOVA fol-
lowed by t-tests whenever comparing more than two
conditions. Asterisks indicate the significance levels as
mentioned in the figure legends.
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